PMID- 37431679
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20240118
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 58
IP  - 6
DP  - 2023 Sep
TI  - Clinical utility of liver fat quantification for determining cardiovascular 
      disease risk among patients with type 2 diabetes.
PG  - 585-592
LID - 10.1111/apt.17637 [doi]
AB  - BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus 
      (T2DM) are independent risk factors for cardiovascular disease (CVD). AIMS: To 
      examine the clinical utility of liver fat quantification for determining CVD risk 
      among a well-phenotyped cohort of patients with T2DM. METHODS: This was a 
      cross-sectional analysis of a prospective cohort of adults aged >/=50 with T2DM. 
      Liver fat was quantified with magnetic resonance imaging 
      proton-density-fat-fraction (MRI-PDFF), an advanced imaging-based biomarker. 
      Patients were stratified into a higher liver fat group (MRI-PDFF >/= 14.6%), and a 
      lower liver fat group (MRI-PDFF < 14.6%). The co-primary outcomes were CVD risk 
      determined by Framingham and Atherosclerotic Cardiovascular Disease (ASCVD) risk 
      scores. High CVD risk was defined by risk scores >/=20%. RESULTS: Of the 391 adults 
      (66% female) in this study, the mean (+/-SD) age was 64 (+/-8) years and BMI 30.8 
      (+/-5.2) kg/m(2) , respectively. In multivariable analysis, adjusted for age, 
      gender, race, and BMI, patients in the higher liver fat group had higher CVD risk 
      [OR = 4.04 (95% CI: 2.07-7.88, p < 0.0001)] and ASCVD risk score [OR = 2.85 (95% 
      CI: 1.19-6.83, p = 0.018)], respectively. CONCLUSION: Higher liver fat content 
      increases CVD risk independently of age, gender, ethnicity and BMI. These 
      findings raise the question whether liver fat quantification should be 
      incorporated into risk calculators to further stratify those with higher CVD 
      risk.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Kuo, Selena Z
AU  - Kuo SZ
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
AD  - Division of Gastroenterology, University of California at San Diego, La Jolla, 
      California, USA.
FAU - Cepin, Sandra
AU  - Cepin S
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
FAU - Bergstrom, Jaclyn
AU  - Bergstrom J
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
FAU - Siddiqi, Harris
AU  - Siddiqi H
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
FAU - Jung, Jinho
AU  - Jung J
AUID- ORCID: 0000-0002-9786-5507
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
FAU - Lopez, Scarlett
AU  - Lopez S
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
FAU - Huang, Daniel Q
AU  - Huang DQ
AUID- ORCID: 0000-0002-5165-5061
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of 
      Singapore, Singapore, Singapore.
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, National 
      University Health System, Singapore, Singapore.
FAU - Taub, Pam
AU  - Taub P
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      California at San Diego, La Jolla, California, USA.
FAU - Amangurbanova, Maral
AU  - Amangurbanova M
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
FAU - Loomba, Rohit
AU  - Loomba R
AUID- ORCID: 0000-0002-4845-9991
AD  - NAFLD Research Center, Division of Gastroenterology, University of California at 
      San Diego, La Jolla, California, USA.
AD  - Division of Gastroenterology, University of California at San Diego, La Jolla, 
      California, USA.
LA  - eng
GR  - 5UL1TR001442/TR/NCATS NIH HHS/United States
GR  - R01DK121378/DK/NIDDK NIH HHS/United States
GR  - R01DK124318/DK/NIDDK NIH HHS/United States
GR  - P30 DK120515/DK/NIDDK NIH HHS/United States
GR  - R01HL136407/HL/NHLBI NIH HHS/United States
GR  - R01 DK124318/DK/NIDDK NIH HHS/United States
GR  - P30DK120515/DK/NIDDK NIH HHS/United States
GR  - U01 DK061734/DK/NIDDK NIH HHS/United States
GR  - P01 HL147835/HL/NHLBI NIH HHS/United States
GR  - R01 DK121378/DK/NIDDK NIH HHS/United States
GR  - R01 DK106419/DK/NIDDK NIH HHS/United States
GR  - U01DK061734/DK/NIDDK NIH HHS/United States
GR  - U01 DK130190/DK/NIDDK NIH HHS/United States
GR  - U01DK130190/DK/NIDDK NIH HHS/United States
GR  - P01HL147835/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001442/TR/NCATS NIH HHS/United States
GR  - U01 AA029019/AA/NIAAA NIH HHS/United States
GR  - R01 DK118278/DK/NIDDK NIH HHS/United States
GR  - R01DK118278-01/DK/NIDDK NIH HHS/United States
GR  - R01 HL136407/HL/NHLBI NIH HHS/United States
GR  - R01DK106419/DK/NIDDK NIH HHS/United States
GR  - U01AA029019/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230711
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
SB  - IM
CIN - Aliment Pharmacol Ther. 2023 Nov;58(10):1109-1110. PMID: 37885163
CIN - Aliment Pharmacol Ther. 2023 Nov;58(10):1107-1108. PMID: 37885164
MH  - Adult
MH  - Humans
MH  - Female
MH  - Male
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis
MH  - Cross-Sectional Studies
MH  - Prospective Studies
MH  - *Cardiovascular Diseases/diagnosis/etiology
MH  - Liver/diagnostic imaging
MH  - *Non-alcoholic Fatty Liver Disease/diagnosis/diagnostic imaging
MH  - Magnetic Resonance Imaging/methods
PMC - PMC10792531
MID - NIHMS1951364
OTO - NOTNLM
OT  - cardiovascular disease risk
OT  - diabetes
OT  - non-invasive imaging
OT  - nonalcoholic fatty liver disease
COIS- RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, 
      Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli 
      Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, 
      Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, 
      Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns 
      Pharmaceuticals and Viking Therapeutics. In addition, his institutions received 
      research grants from Arrowhead Pharmaceuticals, Astrazeneca, 
      Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, 
      Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, 
      Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, 
      Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus 
      Inc. PT serves as a consultant to Amarin, Amgen, Bayer, Boehringer Ingelheim, 
      Edwards, Esperion, Medtronic, Novartis, Novo-Nordisk, and Sanofi and is a 
      shareholder of Epirium Bio.
EDAT- 2023/07/11 06:42
MHDA- 2023/08/28 06:41
PMCR- 2024/01/17
CRDT- 2023/07/11 05:27
PHST- 2022/12/27 00:00 [revised]
PHST- 2022/11/24 00:00 [received]
PHST- 2023/06/27 00:00 [accepted]
PHST- 2023/08/28 06:41 [medline]
PHST- 2023/07/11 06:42 [pubmed]
PHST- 2023/07/11 05:27 [entrez]
PHST- 2024/01/17 00:00 [pmc-release]
AID - 10.1111/apt.17637 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2023 Sep;58(6):585-592. doi: 10.1111/apt.17637. Epub 2023 
      Jul 11.